Eli Lilly and Company (NYSE:LLY) Announces $1.73 Quarterly Dividend

Eli Lilly and Company (NYSE:LLY) announced a quarterly dividend on Monday, May 4th. Stockholders of record on Friday, May 15th will be paid a dividend of 1.73 per share on Wednesday, June 10th. This represents a c) dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, May 15th.

Eli Lilly and Company has raised its dividend payment by an average of 0.2%annually over the last three years and has increased its dividend annually for the last 11 consecutive years. Eli Lilly and Company has a payout ratio of 23.3% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Eli Lilly and Company to earn $41.97 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 16.5%.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $967.49 on Tuesday. The firm has a market cap of $914.11 billion, a price-to-earnings ratio of 34.37, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48. The stock’s 50-day moving average is $947.05 and its 200-day moving average is $987.36. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts predict that Eli Lilly and Company will post 33.79 earnings per share for the current fiscal year.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 beats and guidance lift confidence — Lilly posted a blowout Q1 (revenue +56%) and raised full?year guidance, a primary driver of recent upside as investors price in continued GLP?1 momentum. Read More.
• Positive Sentiment: Market share and Mounjaro strength — Reports show Lilly controls ~60% of the GLP?1 market and Mounjaro revenue surged, underpinning revenue growth and the stock’s valuation re?rating. Read More.
• Positive Sentiment: New long?term Omvoh data supports pipeline diversification — Four?year LUCENT?3 data show durable disease clearance in ulcerative colitis, strengthening Lilly’s non?GLP?1 growth optionality. Read More.
• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms (including Wolfe, Barclays and Cantor Fitzgerald) have reaffirmed/raised ratings and targets, amplifying the bullish narrative after the quarter. Read More.
• Neutral Sentiment: Dividend declared — Board approved a $1.73 quarterly dividend (payable June 10; ex?div May 15), a small yield that supports shareholder returns but is not the main valuation driver. Read More.
• Negative Sentiment: Foundayo safety reports create near?term volatility — FDA logged serious liver?injury cases tied to Lilly’s oral weight?loss pill, triggering headlines and a near?term selloff as investors reassess safety risk and label/usage impacts. Read More.
• Negative Sentiment: Competitive pressure from Novo Nordisk — Wegovy’s pill rollout and proposed compounding limits for GLP?1s give Novo a head start in the oral market; reports of delays to Lilly’s obesity pill add execution risk. Read More.
• Negative Sentiment: Social and media chatter amplified short?term selloffs — Safety chatter and a high volume of online discussion caused intraday swings despite analysts largely calling dips overdone. Read More.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.